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Abstract
Background: Randomised controlled clinical trials typically have a relatively brief in-trial follow-up period which
can underestimate safety signals and fail to detect long-term hazards, which may take years to appear. Extended
follow-up after the scheduled closure of the trial allows detection of both persistent or enhanced beneficial effects
following cessation of study treatment (i.e. a legacy effect) and the emergence of possible adverse effects (e.g.
development of cancer).
Methods: A systematic review was conducted following PRISMA guidelines to qualitatively compare post-trial
follow-up methods used in large randomised controlled trials. Five bibliographic databases, including Medline
and the Cochrane Library, and one trial registry were searched. All large randomised controlled trials (more than
1000 adult participants) published from March 2006 to April 2017 were evaluated. Two reviewers screened and
extracted data attaining > 95% concordance of papers checked. Assessment of bias in the trials was evaluated
using the Cochrane Risk of Bias tool.
Results: Fifty-seven thousand three hundred and fifty-two papers were identified and 65 trials which had post-trial
follow-up (PTFU) were included in the analysis. The majority of trials used more than one type of follow-up. There was
no evidence of an association between the retention rates of participants in the PTFU period and the type of follow-up
used. Costs of PTFU varied widely with data linkage being the most economical. It was not possible to assess
associations between risk of bias during the in-trial period and proportions lost to follow-up during the PTFU period.
Discussion: Data captured during the post-trial follow-up period can add scientific value to a trial. However, there are
logistical and financial barriers to overcome. Where available, data linkage via electronic registries and records is a cost-
effective method which can provide data on a range of endpoints.
Systematic review registration: Not applicable for PROSPERO registration.
Keywords: Methodology, Post-trial, Retention, Randomised controlled trial, Cost, Long-term, Follow-up, Effective
Background
Randomised controlled trials (RCTs) are considered to
be the ‘gold standard‘ for assessing the effects of a treat-
ment. However, these trials usually report results follow-
ing a relatively brief exposure to the intervention under
investigation. Longer-term follow-up of trial participants
is important as persistent effects may be detected years
later after treatment cessation or even enhanced benefits
observed decades later – a so-called ‘legacy effect‘ [1, 2].
Furthermore, delayed hazards may only emerge several
years after exposure to certain treatments. Therefore,
PTFU may add significant scientific value to the evalu-
ation of many healthcare interventions.
We define post-trial follow-up (PTFU) as extended
follow-up which starts after the end of the scheduled
period of the trial. Such follow-up, regardless of the pri-
mary in-trial outcome, provides important information
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including safety of the intervention, identification of de-
layed hazards and long-term beneficial effects.
Retention of participants in PTFU is important since
high rates of attrition may introduce bias if reasons for
withdrawal are related to the intervention [3]. There are
a variety of methods for PTFU, but little research has
been done to evaluate which methods for PTFU leads to
the best retention rates [4]. Choice of follow-up method
is often determined by the funding for the trial and the
local availability of relevant data. Telephone calls, postal
questionnaires and face-to face interviews are the more
traditional approach to follow-up. Web-based ap-
proaches and use of routine health records and elec-
tronic registries are becoming more popular due to
advancing technology and options for accessing the in-
formation inexpensively [5, 6].
This systematic review compares methods used in ap-
proaches to PTFU and aims to inform the design of
PTFU for a wide range of randomised trials. The main
objective was to evaluate the retention rates (or levels of
attrition) of the participants followed up during PTFU
and to compare this to the type of methodology used. A
secondary objective was to compare the costs of post-
trial methodology as funding is often limited.
Methods
The methods used in this systematic review have been
described in detail previously [7] and follow PRISMA
guidelines Additional file 1.
Eligibility criteria
Briefly, all large (> 1000 adult participants) RCTs which
investigated a healthcare intervention (i.e. medicine, sur-
gery or psychiatric in nature) and involved PTFU were
included. Only studies published between 2006 and 2017
were included. Alternative medicines (e.g. acupuncture)
or holistic interventions including physical therapy were
excluded from the review. Large RCTs were only in-
cluded due to the reduced risk of random error in the
outcomes.
PTFU was defined as passive follow-up which had oc-
curred either after the scheduled closure of the trial or
after the primary results had been published.
Search strategy
The search was conducted in five bibliographic data-
bases on 13 April 2017, including Embase (OvidSP) (1
March 1974 to 12 April 2017), Medline (OvidSP) (1946
to present), PubMed, Cochrane Central Register of Con-
trolled Trials (Cochrane Library, Wiley) (issue 3 of 12,
March 2017) and Cochrane Methods Register (CEN-
TRAL) (Cochrane Library, Wiley) (issue 3 of 4, July
2017). Searches were then restricted to articles published
in English since 2006. Full details of strategies are
provided in Additional file 2. In addition, a database
search for completed and ongoing studies was con-
ducted at ClinicalTrials.gov (https://clinicaltrials.gov/).
Studies which were not yet published ‘grey literature’
were not included in the search strategy.
Data collection
Papers identified from the ClinicalTrials.gov registry
were imported into a MS Excel spreadsheet. Duplicates
and studies which had less than 1000 participants were
removed using a filter option. The selection of eligible
papers followed a concordance strategy between two re-
viewers (RLB and DE) which ensured that concordance
was > 95% (Fig. 1) [7].
Medical interventions were defined as an intervention
that was consumed orally, inhaled, or administered by
intravenous or intramuscular injections including vac-
cines. A surgical intervention was defined as any inter-
vention which was invasive (apart from those mentioned
above and including blood transfusions). Potential stud-
ies were checked for eligibility by two reviewers who ini-
tially reviewed abstracts and then proceeded to full
paper review in a step-wise process (Fig. 1).
In addition to those described in the protocol, some
additional exclusions which were not originally listed
were identified during the process of performing the
systematic review in keeping with our definition of
PTFU. This was required due to the heterogeneity of
PTFUs. These include: (1) trials that were stopped be-
fore the scheduled closure of the trial; (2) cancer tri-
als which had an open endpoint (e.g. survival as an
endpoint with no clear scheduled plan of duration);
(3) trials which continued with active intervention in
the PTFU period with the primary outcome of safety
and (4) trials eligible for inclusion but which did not
contribute novel data as they only published add-
itional subgroup or post-hoc analyses. A table of ex-
cluded trials is provided in Additional file 3.
Full papers deemed eligible for inclusion in the sys-
tematic review were extracted using a standardised Excel
spreadsheet. Data was extracted by DE and RLB and
concordance was checked. Primary outcome, healthcare
intervention and attrition rates were tabulated for each
study. Lead trialists were contacted via email to inform
them of the systematic review and to clarify information
where necessary. The papers included in the review were
diverse with a range of interventions and different out-
come measures. Due to the high level of clinical hetero-
geneity a meta-analysis was not possible.
Retention rates were calculated as the proportion of
participants who were lost to follow-up compared to the
overall total of those who started the PTFU period. In-
formation about the cost of the PTFU was sought from
study publications or via personal communication. Two
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attempts were made to contact the trialist via email and
if there was no response or inadequate data, the trial
was excluded from the cost analysis.
Assessment of risk of bias
Risk of bias was assessed for each included RCT on
their primary results using the Cochrane Risk of Bias
tool. Covdence.org was used to assess the levels of bias
(low risk, high risk or unclear risk) in each methodo-
logical domain (sequence generation, allocation of se-
quence concealment, blinding, incomplete outcome
data, selective reporting bias and other bias) and deci-
sions checked by one of the senior authors [8]. The
data recorded from Covidence.org was imported into
Review Manager 5 (RevMan 5) for graphical represen-
tation [9].
Results
From 57,352 papers identified, 65 studies with PTFU
were included in the systematic review (Fig. 1). Fifty
trials involved medical interventions and 15 involved
surgical interventions. There were no eligible psychi-
atric trials which had (all > 1000 participants). The
duration of PTFU ranged from 1 to 20 years, with a
median of 4.5 years of follow-up. The number of par-
ticipants followed during the post-trial period ranged
from 575 to 29 862.
Five methods of follow-up were identified: postal cor-
respondence/questionnaire (19%); clinic appointments
Fig. 1 PRISMA flow diagram detailing the process of study selection and data extraction. HCI healthcare intervention, PTFU post-trial follow-up,
RCT randomised controlled trial
Llewellyn-Bennett et al. Trials  (2018) 19:298 Page 3 of 12
Ta
b
le
1
Po
st
-t
ria
lf
ol
lo
w
-u
p
(P
TF
U
)
in
el
ig
ib
le
m
ed
ic
al
tr
ia
ls
.N
ot
e
re
te
nt
io
n
of
pa
rt
ic
ip
an
ts
ex
pr
es
se
d
as
%
lo
st
to
fo
llo
w
-u
p
1s
t
au
th
or
,
ye
ar
Pr
im
ar
y
ou
tc
om
e
fo
r
PT
FU
RC
T
na
m
e
(P
TF
U
na
m
e)
N
o.
ye
ar
s
PT
FU
a
In
te
rv
en
tio
n
N
o.
ra
nd
om
is
ed
in
-t
ria
l
N
o.
at
th
e
st
ar
t
of
PT
FU
% pa
rt
ic
ip
an
ts
lo
st
in
PT
FU
Ty
pe
of
PT
FU
fo
r
pr
im
ar
y
ou
tc
om
e
Po
st
/
Q
C
lin
ic
Te
le
ph
on
e
D
at
a
lin
ka
ge
Pa
pe
r
re
co
rd
s
O
th
er
A
la
n,
20
15
M
or
ta
lit
y
Pr
oH
O
SP
6
C
A
P
an
tib
io
tic
s
13
59
92
5
6
Y
Y
A
rb
el
,2
01
6
M
or
ta
lit
y
BI
P
20
Be
za
fib
ra
te
30
90
30
90
–
Y
A
rb
er
,2
01
1
C
an
ce
r,
sa
fe
ty
Pr
eS
A
P
2
C
el
ec
ox
ib
15
61
10
43
12
Y
A
ve
ne
ll,
20
12
M
or
ta
lit
y
RE
CO
RD
3
Vi
ta
m
in
D
,C
al
ci
um
52
92
43
94
–
Y
Br
ei
tn
er
,
20
11
A
lz
he
im
er
’s
di
se
as
e
A
D
A
PT
2
N
ap
ro
xe
n,
C
el
ec
ox
ib
25
28
22
33
1
Y
Bu
lb
ul
ia
,
20
11
M
or
ta
lit
y
an
d
m
or
bi
di
ty
H
PS
6
Si
m
va
st
at
in
20
,5
36
17
51
9
0
Y
Y
C
au
le
y,
20
13
H
ip
fra
ct
ur
es
,
ca
nc
er
s,
C
VE
an
d
m
or
ta
lit
y
W
H
I
5
C
al
ci
um
pl
us
vi
ta
m
in
D
36
,2
82
29
86
2
1
Y
C
he
rr
y,
20
14
M
or
ta
lit
y,
ca
nc
er
ES
PI
RI
T
12
O
es
tr
og
en
10
17
10
17
–
Y
C
he
w
,2
01
3
Pr
og
re
ss
io
n
of
ag
e-
re
la
te
d
m
ac
ul
ar
de
ge
ne
ra
tio
n
A
RE
D
S
5
A
nt
io
xi
da
nt
s
47
57
35
49
–
Y
Y
Y
C
ho
w
dh
ur
y,
20
14
D
ia
be
te
s
m
el
lit
us
,
m
or
ta
lit
y,
M
A
C
E
A
N
BP
2
7
A
C
E
in
hi
bi
to
r,
Th
ia
zi
de
60
83
56
78
(6
08
3
lin
ke
d
to
de
at
h
re
gi
st
ry
)
–
Y
Y
C
us
hm
an
,
20
12
M
A
C
E,
m
or
ta
lit
y
A
LL
H
A
T
13
A
m
lo
di
pi
ne
,
lis
in
op
ril
32
,8
04
17
,7
22
(C
VD
),
27
,7
55
(m
or
ta
lit
y)
–
Y
D
ie
ns
ta
g,
20
11
Pr
og
re
ss
io
n
of
H
ep
C
H
A
LT
-C
4
Pe
gi
nt
er
fe
ro
n
10
50
74
3
–
Y
Ea
st
el
l,
20
15
Bo
ne
m
in
er
al
de
ns
ity
H
O
RI
ZO
N
-P
FT
3
Zo
le
dr
on
ic
ac
id
77
65
12
23
–
Y
Y
Eb
bi
ng
,
20
10
M
or
ta
lit
y
N
O
RV
IT
,W
EN
BI
T
4
B
vi
ta
m
in
s
68
45
62
61
0
Y
Ei
ns
te
in
,
20
11
Sa
fe
ty
,
im
m
un
og
en
ic
ity
–
2
H
PV
va
cc
in
e
11
06
67
1
0
Y
–
Er
dm
an
n,
20
14
M
or
ta
lit
y,
M
I,
st
ro
ke
,
M
A
C
E,
(c
om
po
si
te
)
PR
O
ac
tiv
e
3
Pi
og
lit
az
on
e
52
38
35
99
9
Y
Y
Y
Y
Ez
ze
di
ne
,
20
10
Sk
in
ca
nc
er
SU
.V
I.M
A
X
5
A
nt
io
xi
da
nt
vi
ta
m
in
s
12
,7
41
11
05
4
2
Y
Y
Fl
os
sm
an
,
20
07
C
ol
or
ec
ta
lc
an
ce
r
U
K-
TI
A
20
A
sp
iri
n
24
49
22
49
–
Y
Y
C
ol
or
ec
ta
lc
an
ce
r
BD
A
T
20
A
sp
iri
n
51
39
51
39
–
Y
Y
Fo
rd
,2
01
6
M
or
ta
lit
y
an
d
m
or
bi
di
ty
W
O
SC
O
PS
20
Pr
av
as
ta
tin
65
95
57
78
–
Y
Llewellyn-Bennett et al. Trials  (2018) 19:298 Page 4 of 12
Ta
b
le
1
Po
st
-t
ria
lf
ol
lo
w
-u
p
(P
TF
U
)
in
el
ig
ib
le
m
ed
ic
al
tr
ia
ls
.N
ot
e
re
te
nt
io
n
of
pa
rt
ic
ip
an
ts
ex
pr
es
se
d
as
%
lo
st
to
fo
llo
w
-u
p
(C
on
tin
ue
d)
1s
t
au
th
or
,
ye
ar
Pr
im
ar
y
ou
tc
om
e
fo
r
PT
FU
RC
T
na
m
e
(P
TF
U
na
m
e)
N
o.
ye
ar
s
PT
FU
a
In
te
rv
en
tio
n
N
o.
ra
nd
om
is
ed
in
-t
ria
l
N
o.
at
th
e
st
ar
t
of
PT
FU
% pa
rt
ic
ip
an
ts
lo
st
in
PT
FU
Ty
pe
of
PT
FU
fo
r
pr
im
ar
y
ou
tc
om
e
Po
st
/
Q
C
lin
ic
Te
le
ph
on
e
D
at
a
lin
ka
ge
Pa
pe
r
re
co
rd
s
O
th
er
G
er
st
ei
n,
20
16
M
A
C
E,
m
or
ta
lit
y
(c
om
po
si
te
)
A
C
CO
RD
(A
C
C
O
RD
IA
N
)
3
In
te
ns
iv
e
gl
uc
os
e
co
nt
ro
l
10
,2
51
86
01
–
Y
Y
G
lu
ud
,2
00
8
M
or
ta
lit
y
C
LA
RI
C
O
R
3
C
la
rit
hr
om
yc
in
43
73
40
29
1
Y
G
or
do
n,
20
12
Ef
fic
ac
y
an
d
sa
fe
ty
RE
VE
A
L
2
A
da
lim
um
ab
12
12
57
5
7
Y
G
ra
u,
20
09
A
de
no
m
as
A
FP
PS
4
A
sp
iri
n
11
21
10
07
14
Y
Y
G
ru
bb
,2
01
3
C
an
ce
r
RE
D
U
C
E
2
D
ut
as
te
rid
e
82
31
27
51
–
Y
Y
H
ac
ks
ha
w
,
20
11
Ev
en
t-
fre
e
su
rv
iv
al
O
VE
R
50
S
TR
IA
L
10
Ta
m
ox
ife
n
34
49
34
49
–
Y
H
ag
ue
,2
01
6
M
or
ta
lit
y,
ca
nc
er
LI
PI
D
10
Pr
av
as
ta
tin
90
14
77
21
0
Y
Y
Y
Y
Y
H
ay
as
hi
no
,
20
09
D
ia
be
te
s
m
el
lit
us
PH
I1
17
A
sp
iri
n
22
,0
71
22
,0
71
–
Y
Y
H
ay
w
ar
d,
20
15
M
A
C
E
VA
D
T
5
In
te
ns
iv
e
gl
uc
os
e
lo
w
er
in
g
vs
st
an
da
rd
th
er
ap
y
17
91
17
91
22
Y
Y
H
ol
m
an
,
20
08
M
ac
ro
va
sc
ul
ar
ou
tc
om
es
U
KP
D
S
10
In
te
ns
iv
e
gl
yc
ae
m
ic
co
nt
ro
l
38
67
32
77
20
Y
Y
Y
H
or
ns
lie
n,
20
15
St
ro
ke
,M
I,
m
or
ta
lit
y
SC
A
ST
3
C
an
de
sa
rt
an
20
29
12
86
2
Y
In
ve
st
ig
at
or
s,
20
11
D
ia
be
te
s
m
el
lit
us
D
RE
A
M
(D
RE
A
M
O
N
)
2
Ro
si
gl
ita
zo
ne
,
ra
m
ip
ril
52
69
16
53
18
Y
Jo
hn
so
n,
20
15
Va
cc
in
e
ef
fic
ac
y
SP
S
(L
TP
S)
4
Va
cc
in
e
38
,5
43
68
67
6
Y
Y
Jo
ne
s,
20
15
C
an
ce
r,
bo
ne
fra
ct
ur
es
RE
C
O
RD
4
Ro
si
gl
ita
zo
ne
44
47
25
46
1
Y
Y
Y
Ko
st
is
,2
01
1
M
or
ta
lit
y
SH
EP
13
C
hl
or
th
al
id
on
e
47
36
–
–
Y
Kr
an
e,
20
16
M
A
C
E,
m
or
ta
lit
y
(c
om
po
si
te
)
4D
8
A
to
rv
as
ta
tin
12
55
63
7
3
Y
La
i,
20
14
M
or
ta
lit
y,
liv
er
ca
nc
er
A
TB
C
16
α-
to
co
ph
er
ol
,
β-
ca
ro
te
ne
29
,1
33
29
10
5
–
Y
La
te
rr
e,
20
07
M
or
ta
lit
y
A
D
D
RE
SS
1
D
ro
tr
ec
og
in
-α
26
40
26
21
9
Y
Y
Y
Le
sl
ie
,2
01
1
M
or
ta
lit
y
EN
IG
M
A
4
N
itr
ou
s
ox
id
e
20
50
20
02
17
Y
Y
Le
sl
ie
,2
01
5
M
A
C
E,
m
or
ta
lit
y
EN
IG
M
A
-II
1
N
itr
ou
s
ox
id
e
71
12
66
51
12
Y
Y
Le
w
is
,2
01
1
M
A
C
E
C
A
IF
O
S
5
C
al
ci
um
15
10
15
10
–
Y
Llewellyn-Bennett et al. Trials  (2018) 19:298 Page 5 of 12
Ta
b
le
1
Po
st
-t
ria
lf
ol
lo
w
-u
p
(P
TF
U
)
in
el
ig
ib
le
m
ed
ic
al
tr
ia
ls
.N
ot
e
re
te
nt
io
n
of
pa
rt
ic
ip
an
ts
ex
pr
es
se
d
as
%
lo
st
to
fo
llo
w
-u
p
(C
on
tin
ue
d)
1s
t
au
th
or
,
ye
ar
Pr
im
ar
y
ou
tc
om
e
fo
r
PT
FU
RC
T
na
m
e
(P
TF
U
na
m
e)
N
o.
ye
ar
s
PT
FU
a
In
te
rv
en
tio
n
N
o.
ra
nd
om
is
ed
in
-t
ria
l
N
o.
at
th
e
st
ar
t
of
PT
FU
% pa
rt
ic
ip
an
ts
lo
st
in
PT
FU
Ty
pe
of
PT
FU
fo
r
pr
im
ar
y
ou
tc
om
e
Po
st
/
Q
C
lin
ic
Te
le
ph
on
e
D
at
a
lin
ka
ge
Pa
pe
r
re
co
rd
s
O
th
er
Ll
oy
d,
20
13
M
A
C
E,
ca
nc
er
s,
m
or
ta
lit
y
PR
O
SP
ER
3
Pr
av
as
ta
tin
58
04
51
88
–
Y
M
en
ne
,2
01
4
Lo
ng
-t
er
m
m
ic
ro
,
m
ac
ro
va
sc
ul
ar
be
ne
fit
RO
A
D
M
A
P
(R
O
A
D
M
A
P
O
FU
)
3
O
lm
es
ar
ta
n
m
ed
ox
om
il
44
49
21
98
0
Y
O
gi
ha
ra
,
20
11
M
A
C
E,
ca
nc
er
,m
or
ta
lit
y
C
A
SE
-J
(C
A
SE
-J
Ex
)
3
C
an
de
sa
rt
an
,
am
lo
di
pi
ne
47
28
22
32
2
Y
Ra
df
or
d,
20
14
Bo
ne
m
in
er
al
de
ns
ity
A
uc
kl
an
d
C
al
ci
um
St
ud
y
5
C
al
ci
um
14
71
14
08
17
Y
Y
Ro
th
w
el
l,
20
10
C
ol
or
ec
ta
lc
an
ce
r
Th
ro
m
bo
si
s
Pr
ev
Tr
ia
l,
Sw
ed
is
h
A
sp
iri
n
Lo
w
D
os
e
Tr
ia
l,
D
ut
ch
TI
A
A
sp
iri
n
Tr
ia
l,
U
K-
Ti
a
A
sp
iri
n
Tr
ia
l,
Br
iti
sh
D
oc
to
rs
A
sp
iri
n
Tr
ia
l
12
,1
3,
17
,
18
,2
0
A
sp
iri
n
16
,4
88
14
03
3
–
Y
Y
Y
Te
nk
an
en
,
20
06
M
A
C
E,
ca
nc
er
,
m
or
ta
lit
y
H
el
si
nk
iH
ea
rt
St
ud
y
10
G
em
fib
ro
zi
l
40
81
40
81
0
Y
Y
W
an
g,
20
15
Fr
ac
tu
re
in
ci
de
nc
e
N
IT
16
Vi
ta
m
in
s
(1
4)
,
m
in
er
al
s
(1
2)
33
18
33
18
1
Y
Y
W
es
to
n,
20
11
Pe
rs
is
te
nc
e
of
an
tib
od
ie
s
10
63
16
3
Va
cc
in
e
di
p,
pe
rt
,t
et
an
us
22
84
15
05
–
Y
W
hi
te
le
y,
20
14
D
is
ab
ili
ty
IS
T-
3
1
A
lte
pl
as
e
30
35
23
48
2
Y
Zo
un
ga
s,
20
14
M
or
ta
lit
y
A
D
VA
N
C
E
(A
D
VA
N
C
E-
O
N
)
6
Pe
rin
do
pr
il,
in
da
pa
m
id
e
11
,1
40
84
94
–
Y
Y
w
he
re
a
is
nu
m
be
r
of
ye
ar
s
(m
ed
ia
n/
m
ea
n/
m
ax
)
pu
bl
is
he
d
in
th
e
ci
te
d
pa
pe
r,
ye
ar
s
fo
llo
w
ed
up
to
th
e
ne
ar
es
t
w
ho
le
nu
m
be
r,
%
pa
rt
ic
ip
an
ts
lo
st
to
th
e
ne
ar
es
t
w
ho
le
nu
m
be
r,‘
–’
no
da
ta
av
ai
la
bl
e
or
no
t
ap
pl
ic
ab
le
w
he
re
m
or
ta
lit
y
re
co
rd
s
w
er
e
so
ug
ht
,C
VD
ca
rd
io
va
sc
ul
ar
di
se
as
e,
M
A
CE
m
aj
or
ad
ve
rs
e
ca
rd
io
va
sc
ul
ar
ev
en
ts
±
re
va
sc
ul
ar
is
at
io
n,
M
Im
yo
ca
rd
ia
li
nf
ar
ct
io
n.
W
he
re
0
pa
rt
ic
ip
an
ts
ha
ve
be
en
lo
st
to
fo
llo
w
-u
p
th
is
ha
s
be
en
co
nf
irm
ed
ei
th
er
in
th
e
ci
te
d
pa
pe
r
or
di
re
ct
ly
w
ith
th
e
co
rr
es
po
nd
in
g
tr
ia
lis
t
Llewellyn-Bennett et al. Trials  (2018) 19:298 Page 6 of 12
Ta
b
le
2
Po
st
-t
ria
lf
ol
lo
w
-u
p
(P
TF
U
)
in
el
ig
ib
le
su
rg
ic
al
tr
ia
ls
.N
ot
e,
re
te
nt
io
n
of
pa
rt
ic
ip
an
ts
is
ex
pr
es
se
d
as
%
lo
st
to
fo
llo
w
-u
p
1s
t
au
th
or
,y
ea
r
Pr
im
ar
y
ou
tc
om
e
fo
r
PT
FU
RC
T
na
m
e
(P
TF
U
na
m
e)
N
o.
ye
ar
s
PT
FU
a
In
te
rv
en
tio
n
N
o.
pa
rt
ic
ip
an
ts
ra
nd
om
is
ed
in
tr
ia
l
N
o.
pa
rt
ic
ip
an
ts
at
th
e
st
ar
t
of
PT
FU
% pa
rt
ic
ip
an
ts
lo
st
in
PT
FU
M
et
ho
d
of
PT
FU
fo
r
pr
im
ar
y
ou
tc
om
e
Po
st
/Q
C
lin
ic
Te
le
ph
on
e
D
at
a
lin
ka
ge
Pa
pe
r
re
co
rd
s
C
ar
so
n,
20
15
M
or
ta
lit
y
FO
CU
S
3
Bl
oo
d
tr
an
sf
us
io
n
20
16
20
02
–
Y
C
ho
20
17
M
or
ta
lit
y,
M
I,
st
ro
ke
,r
ev
as
cu
la
ris
at
io
n
RI
SP
O
4
RI
PC
,R
IP
os
tC
13
28
12
80
15
Y
Y
Y
G
ad
a,
20
13
Sa
fe
ty
,e
ffi
ca
cy
,m
or
ta
lit
y
SP
IR
IT
III
5
EE
S,
PE
S
10
02
–
–
Y
G
al
la
gh
er
,2
01
4
M
or
ta
lit
y
RE
N
A
L
(P
O
ST
-R
EN
A
L)
4
Re
na
lr
ep
la
ce
m
en
t
th
er
ap
y
15
08
14
64
–
Y
H
al
lid
ay
,2
01
0
M
or
ta
lit
y,
st
ro
ke
A
C
ST
-1
4
C
EA
or
de
fe
re
m
en
t
31
20
31
20
–
Y
H
en
de
rs
on
,2
01
5
M
or
ta
lit
y
RI
TA
-3
5
PC
I
18
10
18
10
0
Y
H
irs
ch
,2
00
7
M
or
ta
lit
y,
M
A
C
E
IC
TU
S
4
PC
I
12
00
11
24
3
Y
Y
Y
H
oc
hm
an
,2
01
1
M
or
ta
lit
y,
M
A
C
E
O
A
T
3
PC
I
22
01
15
04
–
Y
Y
Y
In
ve
st
ig
at
or
s,
20
07
M
or
ta
lit
y
BA
RI
5
PT
C
A
18
29
18
29
4
Y
Y
Y
M
ilo
je
vi
c,
20
16
M
or
ta
lit
y
SY
N
TA
X
5
PC
I
18
00
84
7
–
Y
Y
Y
N
au
nh
ei
m
,2
00
6
M
or
ta
lit
y
N
ET
T
2
Lu
ng
-v
ol
um
e
su
rg
er
y
12
18
70
%
–
Y
Y
Pa
te
l,
20
16
M
or
ta
lit
y
EV
A
R-
1
13
EV
A
R
12
52
12
52
2
Y
Y
Y
Po
w
el
l,
20
07
M
or
ta
lit
y
U
KS
A
T
12
Ea
rly
A
A
A
re
pa
ir
10
90
10
90
0
Y
Se
dl
is
,2
01
5
M
or
ta
lit
y
C
O
U
RA
G
E
6
PC
I
22
87
12
11
–
Y
W
al
le
nt
ei
n,
20
16
M
or
ta
lit
y,
M
I(
co
m
po
si
te
)
FR
IS
C
-II
15
PC
I
24
57
24
21
1
Y
Y
w
he
re
a
is
nu
m
be
r
of
ye
ar
s
(m
ed
ia
n/
m
ea
n/
m
ax
)
pu
bl
is
he
d
in
th
e
ci
te
d
pa
pe
r,
ye
ar
s
fo
llo
w
ed
up
to
th
e
ne
ar
es
t
w
ho
le
nu
m
be
r,
PC
Ip
er
cu
ta
ne
ou
s
co
ro
na
ry
in
te
rv
en
tio
n
±
re
va
sc
ul
ar
is
at
io
n
,P
TC
A
pe
rc
ut
an
eo
us
tr
an
sl
um
in
al
co
ro
na
ry
ba
llo
on
an
gi
op
la
st
y,
EE
S
ev
er
ol
im
us
-e
lu
ti
ng
st
en
ts
,P
ES
pa
cl
ita
xe
l-e
lu
tin
g
st
en
ts
,E
VA
R
en
do
va
sc
ul
ar
an
eu
ry
sm
re
pa
ir,
CE
A
ca
ro
tid
en
da
rt
er
ec
to
m
y,
A
A
A
ab
do
m
in
al
ao
rt
ic
an
eu
ry
sm
,R
IP
C
re
m
ot
e
is
ch
ae
m
ic
pr
ec
on
di
tio
ni
ng
,R
IP
os
tC
RI
PC
w
ith
po
st
co
nd
iti
on
in
g,
M
Im
yo
ca
rd
ia
li
nf
ar
ct
io
n,
M
A
CE
m
aj
or
ad
ve
rs
e
ca
rd
io
va
sc
ul
ar
ev
en
ts
±
re
va
sc
ul
ar
is
at
io
n,
Po
st
al
/Q
po
st
al
co
m
m
un
ic
at
io
n
or
qu
es
tio
nn
ai
re
,y
ea
rs
fo
llo
w
ed
up
to
th
e
ne
ar
es
t
w
ho
le
nu
m
be
r,
%
pa
rt
ic
ip
an
ts
lo
st
to
th
e
ne
ar
es
t
w
ho
le
nu
m
be
r,
70
%
pr
ov
id
ed
by
tr
ia
lis
t.
W
he
re
0
pa
rt
ic
ip
an
ts
ha
ve
be
en
lo
st
to
fo
llo
w
-u
p
th
is
ha
s
be
en
co
nf
irm
ed
ei
th
er
in
th
e
ci
te
d
pa
pe
r
or
di
re
ct
ly
w
ith
th
e
co
rr
es
po
nd
in
g
tr
ia
lis
t
Llewellyn-Bennett et al. Trials  (2018) 19:298 Page 7 of 12
(35%); telephone interviews (26%); electronic data link-
age (52%); and review of paper medical records (26%). In
addition, in individual cases, specific follow-up was per-
formed, e.g. endoscopy follow-up only [10]. Electronic
data linkage and medical records review were used ex-
clusively together in 11% of papers; either were used in
combination with other methods in 74%. Overall, 48% of
trials used more than one method to follow-up partici-
pants in the post-trial period (Tables 1 and 2). On aver-
age, two methods were used for each PTFU follow-up.
Where data linkage was used, it was not always feasible
to follow up all participants [11]. Some trials experi-
enced difficulty accessing national electronic data in cer-
tain countries; for example, stricter regulations are
apparent in Canada and for some North American par-
ticipants (Medicare and Veteran Affairs) where a specific
health ID number is required to access national data
(Table 3). Trials experienced difficulty in accessing rou-
tinely collected health records in 3% of included papers
and PTFU was restricted to those countries with robust
and accessible centrally held records and registries (e.g.
Sweden and Scotland) [12, 13].
Retention rates
Unfortunately, retention rates were often poorly re-
ported in the PTFU, limiting the ability to assess the im-
pact of methods used in relation to the proportion lost
to follow-up.
Table 3 Registries used for data linkage during post-trial follow-up (PTFU)
Country Registry Dataset Website
USA United States Renal Data System
(USRDS)
Renal www.usrds.org
Centres for Medicare and Medicaid
Services (CMS ([formerly HCFA))a
Non-fatal events www.cms.gov
National Death Index Plus Database Cause- specific mortality https://www.cdc.gov/nchs/ndi/
National Death Index and Social
Security Administration
All-cause mortality https://www.cdc.gov/nchs/nvss/deaths.htm
The Central Veterans Affairs Medical
Information files
All-cause morbidity https://www.va.gov/directory/guide/
facility.asp?ID=5380
The Veterans Affairs Death Files All-cause mortality https://www.archives.gov/research/
alic/reference/vital-records.html
Canada Statistics Canada Mortality Database All-cause mortality http://www23.statcan.gc.ca/imdb/
p2SV.pl?Function=getSurvey&
SDDS=3233
England NHS Digital (formerly HSCIC and Office
of National Statistics)
Non-fatal events,
all-cause mortality
https://digital.nhs.uk/
Scotland Information and Statistical Division of the
National Health Service for Scotland
(Scottish Morbidity Record, General
Register Office Death Record)
All-cause morbidity,
mortality
http://www.isdscotland.org/
Israel Ministry of Health from the Israeli
Population Registry
All-cause mortality https://www.health.gov.il/English/
Pages/HomePage.aspx
Israel National Cancer Registry Cancer https://www.health.gov.il/English/
MinistryUnits/HealthDivision/Icdc/
Icr/Pages/default.aspx
Holland Dutch Central Bureau of Statistics All-cause mortality http://www.iamexpat.nl/expat-page/
official-issues/organisations/statistics-
netherlands-cbs
Norway Cardiovascular Disease in Norway
(CVDNOR) project (for data < 2008)b
Cause-specific
morbidity
https://cvdnor.b.uib.no/
Finland Cause-of-Death Register
(Statistics Finland)
All-cause mortality http://tilastokeskus.fi/til/ksyyt/
index_en.html
Population Register Centre c Demographics http://vrk.fi/en/frontpage
Finnish Cancer Registry Cancer http://www.cancer.fi/
syoparekisteri/en/
Australia Western Australia Data Linkage
System (WADLS)
Non-fatal events,
all-cause mortality
http://www.datalinkage-wa.org.au/
a Data only available for those with a valid Medicare or Social Security number (65% of all participants in the ALLHAT long-term follow-up), bRegistry linkage in
Norway only available from 2008, c A personal identification number issued to each Finnish resident accesses demographic and medical records
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All surgical trials investigated mortality as the primary
outcome and, where data was available, the proportion of
participants lost to follow-up in surgical trials ranged from
0.4 to 15.5%. However, data was not available for 53% of
surgical trials. In medical trials, the primary outcome in-
vestigated varied more widely, although mortality as an
endpoint was common and the proportion of participants
lost to follow-up ranged from 0 to 22%. Data on loss to
follow-up was not available in 44% of trials. Where
mortality was the primary outcome, the number of partici-
pants lost to follow-up was not available in 32% of trials
due to the use of mortality records where only notifica-
tions of deaths were fed back to the trialists.
Cost
Financial information was available for one third of
the included trials. Consequently, it was not possible
to provide a direct comparison between cost of PTFU
and the different methodologies used due to the small
sample size. The cost of PTFU ranged from £6000 to
£14,600,000 (Table 4). Cost of PTFU per participant
per year showed that IST-3 was the most economical
Table 4 Comparing post-trial follow-up (PTFU) costs (where disclosed), by different follow-up methodologies
Type of follow-up,
name of
RCT or PTFU
Number of
participants
in PTFU
Duration
of PTFU*
Incentive for participant
follow-up
Cost of PTFU/grant received Cost per
participant
per year
Clinical appointment only
ROADMAP 2198 3.3 Travel reimbursement €20 per visit €3,000,000 €413.60
Clinical appointment + telephone
LTPS 6867 4 – US$14,600,000 US$531.53
Data linkage/medical records only
RECORD 4394 3 No £6,000 £0.46
FOCUS 2002 3 No US$75,000 US$12.49
NORWIT, WENBIT 6261 4 Letters sent to offer
withdrawal from PTFU
(registry follow-up)
NOK 16,000 NOK 0.64
RENAL 1464 4 No Undisclosed – original recruiting sites
paid for finding and contacting participants
CLARICOR 4029 3 – £1,100,000 £91.01
‘Over 50s’ 3449 10 no £14,000 £0.41
RITA-3 1810 5 – £359,577 £39.73
SCAST 1286 3 no £7,000 €1.81
CAIFOS 1510 4.5 no AUD 848,206 AUD 124.83
IST-3 2348 1 no £500 £0.21
Telephone + data linkage/medical records
ProHOSP 925 6 no Negligible. Students conducted telephone
follow-up as part of their training
–
OAT 1504 3 no US$100 administrative start-up, US$50 per call
for each follow-up, US$30 per subject for re-consent
payment, US$300 per event completing reporting
–
ENIGMA 2002 3.5 no AUD 53,807 AUD 7.68
ENIGMA-II 6651 1 no AUD 60,000 AUD 9.02
Postal correspondence + data linkage/medical records
HPS 17,519 6 – £250,000 £2.38
ANBP2 6983 6.9 no AUD 18,000 AUD 0.37
ACST-1 3120 4 – £120,000 £9.62
VADT 1791 5 US$10 per survey gift card US$10,00,000 US$111.67
Postal correspondence +telephone + medical records
ADDRESS 2621 1 no US$13,10,500 US$500
where a; median/max/range published in the cited paper, RCT randomised controlled trial, PTFU post-trial follow-up, NOK Norwegian Krone, AUD Australian dollar;
‘-’ no data available/ declined by corresponding trialist, ‘~‘ ,estimate; + RCT number as PTFU data not available. Results to 2 decimal places for cost per participant
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costing £0.21 per participant per year using data
linkage/medical records, closely followed by ‘Over
50s’ (£0.41) and RECORD trials (£0.46) which also
used data linkage. LTPS was the most expensive
PTFU per participant per year (US$531.53) using clin-
ical appointments and telephone follow-up. ROAD-
MAP which also followed up participants by clinic
appointment only had a cost of €413.60 per partici-
pant per year.
Cochrane Risk of Bias
We hypothesised that those RCTs which had poor
methodology or ‘high risk of bias’ might subse-
quently have a PTFU which was poorly organised
and, therefore, have low retention rates (or a high
proportion lost to PTFU). Of the 65 papers included
in the systematic review, seven were excluded from
the risk of bias assessment: these were PTFUs which
followed-up an amalgamation of data from more
than one trial or were part of a systematic review
and, therefore, not suitable to be included in the
analysis (the risks of bias from individual component
trials could not be combined).
Of the 58 trials considered, the risk of bias could not
be fully assessed in 11 trials due to lack of information
in at least one domain. Low (or unclear) risk of bias in
all domains was found in 43 (74%) of those assessed.
Only seven trials (12%) had at least one domain which
was high risk of bias, of which one had two domains at
high risk (Fig. 2). Details of the individual risk of bias
domains for each included study are provided in
Additional file 4.
Given the small number of trials found to have a high
risk of bias in at least one domain and the highly vari-
able retention rates observed during PTFU (Table 5), it
is not possible to draw any clear conclusions with
respect to possible associations between risk of bias and
its potential impact on the proportion of participants
that were lost to follow-up in the post-trial period.
Discussion
This systematic review identified that PTFU methods
varied and many trials used overlapping approaches
which were more costly than needed. Data was limited
on retention rates and so it was difficult to draw any
firm conclusions on which method was best for PTFU.
Our main findings suggest that most PTFU published in
the last 11 years does not appear to be designed in a cost-
effective manner. Cost of PTFU was shown to vary widely
and not many trials used incentives to retain participants.
Despite only a third of trialists providing complete financial
Fig. 2 Cochrane Risk of Bias graph. Review authors’ judgements about each risk of bias item presented as percentages across all included studies
Table 5 Comparison of randomised controlled trials (RCTs) which had high risk of bias compared to the proportion lost to
follow-up during post-trial follow-up (PTFU). A summary of those RCTs with no risk of bias are also detailed
High-risk domain Number of studies with high-risk domain Proportion of participants lost to follow-up during PTFU (%)
Blinding participants and personnel 3 3.96–6.16
Incomplete outcome data 2 –
Other sources of bias 3 1.21–11.79
Selective outcome reporting 1 1.2
Low risk of bias in all domains 43 (no high/unclear risk of bias) 0–19.90
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information for PTFU, follow-up by clinical appointment
appeared to be the most expensive method, as might be ex-
pected given the resource implications. Postal or telephone
correspondence in addition to data linkage did not appear
to increase the cost per participant per year considerably.
However, the effect of inflation over the 11 years included
in this systematic review, makes quantitative comparison of
cost differences difficult. Given the limited data available we
have not attempted to adjust for inflation.
Data linkage or access to medical records is likely to be
the most cost-effective method of following participants
due to minimal staff required. However, a number of trial-
ists highlighted the limitations of this approach, noting it
to be time-consuming and frustrating with increasing
regulatory costs and country-specific restrictions. In
the UK, the process of accessing data electronically
has become more stringent and costly, and markedly
different to the processes which were encountered
10 years ago. There is also an issue of the data lag-
ging behind by up to 2 years in some countries,
which can impact on the completeness of results for
a trial. Despite this, data linkages to national regis-
tries and electronic health records have been shown
to be a valid and reliable method of PTFU [12–15].
When designing this systematic review, we anticipated
that papers published in the early half of the last 11 years
would choose more traditional methods of PTFU, e.g.
clinic- and telephone-based approaches, and more re-
cent trials may increasingly use data linkage where avail-
able. However, this has not been the case. The majority
of trials have used a variety of different methods to cap-
ture data for the same primary outcome. We were,
therefore, unable to compare retention rates by each
type of method used. In addition, sparsity of complete
data in the review (typically poor reporting of the final
number of participants at the end of the follow-up
period) limited the ability to assess retention rates
achieved with different PTFU methods.
We found limited evidence of high risk of bias in the
methodology of the in-trial periods. A likely explanation
for this is that the majority of the trials included in this
review were well-designed, large RCTs in which results
were published in high-impact journals. Furthermore,
trials which employ poor methodology or have had
negative results are more likely not to engage in PTFU
due to lack of funding or interest.
Due to new guidelines (Consolidated Standards of
Reporting Trials (CONSORT)) recommending increas-
ing transparency in the reporting of RCTs, a more
complete capture of data would be likely for any future
study [16]. Research into appropriate methods in PTFU
can only occur if there is transparency of the logistical
and financial implications including number of partici-
pants lost to follow-up.
Conclusions
Post-trial follow-up of large RCTs can contribute signifi-
cantly to the scientific value of a trial by determining the
longer-term magnitude of the effects of an intervention.
PTFU is valuable to ensure that there are no long-term
hazards or beneficial effects which have been missed due
to the common short in-trial periods for following up
participants. However, it is not widely used as shown by
the small number of eligible trials which had PTFU from
the original search strategy.
Data linkage and the use of registries appear to be the
most plausible and economical approach to PTFU. These
methods also have the advantage of providing data for a
wide range of endpoints. Improvement of electronic
reporting and informatics could lead to better reporting
and allow this type of method to be widely used.
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